Patents for A61P 35 - Antineoplastic agents (221,099)
05/2004
05/13/2004US20040092517 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
05/13/2004US20040092515 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
05/13/2004US20040092506 Administering estrogen antagonist; skin disorders; wrinkle resistance; antiarthritic agents; anticancer agents; wound healing agents
05/13/2004US20040092505 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
05/13/2004US20040092497 Heteroarylakanoic acids as intergrin receptor antagonists
05/13/2004US20040092486 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
05/13/2004US20040092478 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
05/13/2004US20040092476 Anticancer agents; viricides
05/13/2004US20040092454 3-biphenyl-4-yl-3-(2-(4-(pyridin-2-ylamino)pentanoylamino)-pen tanoyl amino)propionic acid derivatives
05/13/2004US20040092453 Synergistic antineoplastic effect; side effect reduction
05/13/2004US20040092434 Oligopeptides; antitumor agents, antiinflammatory agents, antiischemic agents, vision defects
05/13/2004US20040092433 Use of zwitterionic polysaccharides for the specific modulation of immune processes
05/13/2004US20040092430 Antitumor agents; antiinflammatory agents; autoimmune disease
05/13/2004US20040091996 Genetically engineered virus which propagates specifically in tumor cells and codes angiogensis inhibitors; antitumor/antiproliferative agents
05/13/2004US20040091967 Regulation of human histone acetyltranseferase
05/13/2004US20040091964 Modified proteins, isolated novel peptides,and uses thereof
05/13/2004US20040091955 Process and compositions for peptide, protein and peptidomimetic synthesis
05/13/2004US20040091951 Assay for measuring acetylation or deacetylation activity of an enzyme
05/13/2004US20040091947 Screening strategy for anticancer drugs
05/13/2004US20040091912 Diagnostic method
05/13/2004US20040091907 GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof
05/13/2004US20040091895 Human sprouty-4 polypeptide
05/13/2004US20040091890 Life sciences business systems and methods
05/13/2004US20040091878 Zinc finger domain recognition code and uses thereof
05/13/2004US20040091555 Methods for producing agrimonia extracts with improved activity against hepatitis b virus and pharmaceutical and food compositions containing said extracts
05/13/2004US20040091522 Lipid microparticles by cryogenic micronization
05/13/2004US20040091489 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
05/13/2004US20040091485 Humanised antibodies to the epidermal growth factor receptor
05/13/2004US20040091484 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
05/13/2004US20040091479 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
05/13/2004US20040091468 Novel transcriptional mediators of blood vessel development and endothelial differentiation
05/13/2004US20040091464 Isolated stromal cells for use in the treatment of diseases of the central nervous system
05/13/2004US20040091463 Sensitization of neoplastic cells to radiation therapy with reovirus
05/13/2004US20040091458 Method for reducing pain using oncolytic viruses
05/13/2004US20040091457 Compositions and methods for inhibiting viral replication
05/13/2004US20040091423 Methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or
05/13/2004US20040091421 The invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable
05/13/2004CA2504653A1 Aminated isoflavonoid derivatives and uses thereof
05/13/2004CA2504178A1 Methods and kits for diagnosing tumorigenicity
05/13/2004CA2503422A1 Compositions for cancer treatment
05/13/2004CA2501701A1 Chemotherapeutic agent-incorporated pharmaceutical preparation
05/12/2004EP1418431A1 Nuclear pore protein Nup88 as a novel target
05/12/2004EP1418293A1 System for the construction of water retaining walls, such as swimming pool walls, with prefabricated panels
05/12/2004EP1418184A1 Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
05/12/2004EP1418177A1 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions
05/12/2004EP1417974A1 Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
05/12/2004EP1417968A2 Antitumour compositions containing propolis and resveratrol
05/12/2004EP1417964A1 Antitumor agent containing cyclic polylactic acid
05/12/2004EP1417353A1 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
05/12/2004EP1417350A2 Antisense modulation of hormone-sensitive lipase expression
05/12/2004EP1417342A2 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
05/12/2004EP1417328A2 Invasion complex and methods of targeting
05/12/2004EP1417323A2 Humanised baculovirus
05/12/2004EP1417308A1 Human protooncogene kg-20 and protein encoded therein
05/12/2004EP1417307A2 Oligonucleotide compositions and their use to induce apoptosis
05/12/2004EP1417304A2 Method and composition for inhibiting heparanase activity
05/12/2004EP1417300A1 Process for the maturation of dentritic cells and a vaccine
05/12/2004EP1417236A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
05/12/2004EP1417232A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
05/12/2004EP1417231A2 Modified human thymic stromal lymphopoietin
05/12/2004EP1417229A2 Methods and compounds for the targeting of protein to exosomes
05/12/2004EP1417228A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/12/2004EP1417227A2 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/12/2004EP1417217A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors
05/12/2004EP1417214A2 Cancer specific oligosaccharide sequences and use thereof
05/12/2004EP1417211A2 Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses
05/12/2004EP1417205A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
05/12/2004EP1417201A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
05/12/2004EP1417196A1 Dna-pk inhibitors
05/12/2004EP1417195A1 Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors
05/12/2004EP1417191A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
05/12/2004EP1417185A2 2-adamantyl-4,6-diamino-1,2-dihydro-1-aryl-1,3,5-triazine derivatives as cell proliferation inhibitors
05/12/2004EP1417183A1 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
05/12/2004EP1417181A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
05/12/2004EP1417177A2 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
05/12/2004EP1417173A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
05/12/2004EP1417169A2 Selective estrogen receptor modulators
05/12/2004EP1417055A2 Use of copper chelators to inhibit the inactivation of protein c
05/12/2004EP1416974A1 Gas microsphere liposome composites
05/12/2004EP1416970A2 Conjugate
05/12/2004EP1416964A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
05/12/2004EP1416960A1 Vegfr-1 antibodies to treat breast cancer
05/12/2004EP1416959A2 Liposomes prepared from the extractable lipids from a mycobacterium
05/12/2004EP1416954A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
05/12/2004EP1416951A1 Melanin-concentrating hormone antagonists
05/12/2004EP1416945A1 Improved heteropolymer complexes and methods for their use
05/12/2004EP1416941A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
05/12/2004EP1416940A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
05/12/2004EP1416939A2 Method of treating malignancy associated hypercalcemia using active vitamin d analogues
05/12/2004EP1416936A1 Thiopyrane-4-ones as dna protein kinase inhibitors
05/12/2004EP1416935A1 4-amino-6-phenyl-pyrrolo 2,3-d]pyrimidine derivatives
05/12/2004EP1416934A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
05/12/2004EP1416933A1 Substituted piperidines as modulators of the melanocortin receptor
05/12/2004EP1416931A1 Inhibitors of polyq-aggregation
05/12/2004EP1416929A2 Cancer treatment with gö6976 and its related compounds
05/12/2004EP1416928A2 N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
05/12/2004EP1416885A2 Methods and devices for delivery of therapeutic capable agents with variable release profile
05/12/2004EP1416884A2 Delivery of therapeutic capable agents
05/12/2004EP1367046A9 Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs
05/12/2004EP1303284A4 Compositions and methods for the treatment of skin damage